1/2 🔥🚨Hot off the press. U.S. FDA approves #Pembrolizumab for #Adjuvant therapy for 1 year (post chemotherapy) for #Patients with resected stage IB, II, IIIA Non-Small Cell #LungCancer (#NSCLC) regardless of #PDL1 level, based on #Keynote 091 study. fda.gov/drugs/resource…

Happy to contribute to this #NatureCommunications article on #NSCLC treatment. The large cohort study showed concurrent chemo-#Immunotherapy may protect against early progression but doesn’t affect overall survival. nature.com/articles/s4146…

Although it’s cold and rainy in Copenhagen, feeling the heat in #ELCC23 lung cancer conference. A big discrepancy in audiences in choosing 1st line therapy for EGFR ex20ins LUAD. Speaker Dr Girard chose chemo+bev to avoid immunotherapy. ESMO - Eur. Oncology IASLC

Fresh and hot updates at #ELCC23 on CM816, showing persistent benefits of neoadjuvant Nivo+chemo in resectable NSCLC. Interestingly, the benefits seem more in preventing distal metastasis rather than local recurrence. What could be a possible explanation?Nicolas Girard ESMO - Eur. Oncology

🆕in Clinical Cancer Research an analysis investigating the efficacy of Osi in pts with lung cancer harbouring *uncommon* EGFR exon 19 del mut’s E746_A750del was associated with significantly prolonged mPFS with 1L Osi vs. L747_A750>P (21.3 vs. 11.7m; [HR] 0.52 ; p=0.043). Understanding

At #ASCO23 Dr. Rami Manochakian MD, FASCO Cancer Education, thoracic oncologist & vice chair for education at Mayo Clinic in Florida, presented in an education session on integrating #LearningScience principles and how to "ACE" teaching through oncology presentations to make them memorable and effective.

🔥🚨OncoAlert #ASCO23 NEGATIVE results of #Keynote789 trial: Platinum + Pem +/- Pembro for TKI-resistant #EGFR mutant #NSCLC ❌PFS HR 0.8, P=0.0122 mPFS: 5.6 vs 5.5 mths ❌OS HR 0.84, P=0.0362 mOS: 15.9 vs 14.7 mths After TKI , adding Pembro to chemo DOES NOT improve OS

#ASCO23 🫁WU-KONG6: Phase 2 Sunvozertinib for EGFR Exon20Ins 1⃣ORR 60.8% (48.5% in pts w/ brain mets) 2⃣ORR consistent across loop location 3⃣Median DOR not reached after median f/u at 7.1 mos for responders ✅A new promising drug for EGFR Exon20Ins

Great work by Lova Sun Charu Aggarwal, MD, MPH, FASCO published during #ASCO23 . Answered a clinical-relevant question that many practicing oncologists are waiting for. Congrats!

🔥🚨OncoAlert Just out JTO & JTO CRR by our team Mayo Clinic Comprehensive Cancer Center: #CaseReport on a sequential #SmallCell transformation & #ALK I1171T mutation as resistance mechanisms in a pt with #ALK-EML4 #NSCLC treated with combination of #Temozolomide & #Lorlatinib 👇🏼 jtocrr.org/article/S2666-…

JAMA Oncology 3/3 Very proud of 1st author Dr. Li Shenduo Li, MD, PhD (outstanding #HemOnc fellow and future thoracic oncologist).

Our incoming chief fellow Dr. Tanmayi Pai is moderating a work life balance discussion for all trainees and early career faculty 👏👏👏 #ASCO24 ASCO Mayo Clinic Mayo Clinic Comprehensive Cancer Center